CD69 and lung carcinoma: Here, analysis of CTR-DB data showed that CD69 is upregulated in lung cancer and melanoma patients who respond to PD-1/PD-L1 blockade, highlighting its potential as a predictor of pan-cancer response to anti-PD-1/PD-L1 immunotherapy.